-
Elon Musk Says Ozempic 'Will Become Very Cheap' After New Comedy Special Paints It As Weight Loss Drug Only Wealthy People Can Afford
Saturday, May 25, 2024 - 4:30am | 591Tesla and SpaceX CEO Elon Musk made a bold prediction about the future cost of Novo Nordisk’s (NYSE:NVO) Ozempic, a popular drug being used for weight loss. What Happened: Musk’s comments came after a new South Park special portrayed the drug as a luxury only available to the wealthy....
-
Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds
Friday, May 24, 2024 - 2:03pm | 464Friday, Eli Lilly And Company (NYSE:LLY) announced it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion. This...
-
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
Monday, May 20, 2024 - 9:34am | 514Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (semaglutide). The study, presented at the Digestive Disease Week meeting in...
-
Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate
Friday, May 3, 2024 - 3:45am | 750Amgen, Inc. (NASDAQ:AMGN) shares rallied over 14% in Thursday’s after-hours trading after the biopharma reported a double beat and offered an update on its obesity drug pipeline. What Happened: Amgen said on the call that it was pulling the plug on AMG 786, an oral Phase 1 candidate for...
-
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy
Wednesday, April 3, 2024 - 4:07pm | 659After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs. Eli Lilly shares have climbed 162%...
-
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Monday, February 26, 2024 - 12:31pm | 655The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the Danish company’s shares 30% higher. Zealand Pharma’s survodutide drug showed positive results...
-
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
Wednesday, January 31, 2024 - 9:49am | 804Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors with earnings and revenue beats thanks, in large part, to the overwhelming success of its diabetes treatments that have become popular weight-loss...
-
Is Your Weight-loss Medication Genuine? Demand For Drugs From Novo Nordisk And Eli Lilly Leads To Surge In Counterfeits
Saturday, October 21, 2023 - 9:56pm | 779As obesity rates climb worldwide, so does the demand for weight-loss medications like Novo Nordisk's (NYSE: NVO) Ozempic and Eli Lilly And Company's (NYSE: LLY) Mounjaro. This heightened demand, however, has spurred a troubling rise in counterfeit drugs,...
-
Novo Nordisk Ups Outlook Amid Surging Demand For Weight Loss Drug Wegovy, Ozempic
Saturday, October 14, 2023 - 12:23am | 311Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Danish pharmaceutical company Novo Nordisk (NYSE:NVO) has revised its full-year sales and operating profit outlook. Novo Nordisk is now forecasting a sales growth for 2023 in local currencies of 32% to 38...